Christer Groeben

Dr. Christer Groeben


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2016 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
CGChrister Groeben
Christer Groeben
RKRainer Koch
Rainer Koch
MBMartin Baunacke
Martin Baunacke
MWManfred P. Wirth
Manfred P. Wirth
JHJohannes Huber
Johannes Huber

21 February 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CGChrister Groeben
Christer Groeben
RKRainer Koch
Rainer Koch
MBMartin Baunacke
Martin Baunacke
MSMarianne Schmid
Marianne Schmid
ABAngelika Borkowetz
Angelika Borkowetz
JHJohannes Huber
Johannes Huber

17 September 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MBMartin Baunacke
Martin Baunacke
MSMaria-Luisa Schmidt
Maria-Luisa Schmidt
CTChristian Thomas
Christian Thomas
CGChrister Groeben
Christer Groeben
ABAngelika Borkowetz
Angelika Borkowetz
JHJohannes Huber
Johannes Huber

30 January 2019 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
CGChrister Groeben
Christer Groeben
RKRainer Koch
Rainer Koch
MBMartin Baunacke
Martin Baunacke
ABAngelika Borkowetz
Angelika Borkowetz
MWManfred P. Wirth
Manfred P. Wirth
JHJohannes Huber
Johannes Huber
Background: Radical cystectomy (RC) still poses a significant risk for mortality and morbidity. Objectives: We compared in-hospital outcomes after RC in the United States and ­Germany using population-based data. Methods: We compared data from the US Nationwide Inpatient Sample to the German hospital billing database. Mortality and transfusion during hospital stay and length of stay (LOS) were evaluated. Results: In all, 17,711 (the United States) and 60,447 (­Germany) cases were included. The share of robot-assisted RC increased to 20.5% in the United States vs. 2.3% in Germany (p < 0.001). In-hospital mortality was 1.9% (the United States) vs. 4.6% (Germany), transfusion rates were 34.2% (the United States) vs. 58.7% (Germany), and LOS was 10.7 (the United States) vs. 25.1 days (Germany; all p < 0.001). On multivariate analysis, higher patient age and lower annual hospital caseload were associated with increased mortality and longer LOS. Minimal-invasive surgery was associated with less blood transfusion and shorter LOS in the United States vs. hospital caseload and choice of urinary diversion in Germany. Conclusions: Healthcare systems might exert a relevant impact on outcomes of oncologic surgery. Increased in-hospital mortality rates in Germany seem to be partly explained by much longer LOS compared to those in the United States. Annual caseload seems to be influential on in-hospital outcomes raising the question of centralization of RC.

11 October 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
CGChrister Groeben
Christer Groeben
RKRainer Koch
Rainer Koch
TNTim Nestler
Tim Nestler
KKKlaus Kraywinkel
Klaus Kraywinkel
ABAngelika Borkowetz
Angelika Borkowetz
JHJohannes Huber
Johannes Huber

16 January 2018 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
ABAngelika Borkowetz
Angelika Borkowetz
TRTheresa Renner
Theresa Renner
IPIvan Platzek
Ivan Platzek
MTMarieta Toma
Marieta Toma
RHRoman Herout
Roman Herout
MWManfred P. Wirth
Manfred P. Wirth
Introduction: Targeted biopsy of tumour-suspicious lesions detected in multiparametric magnetic resonance imaging (mpMRI) plays an increasing role in the active surveillance (AS) of patients with low-risk prostate cancer (PCa). The aim of this study was to compare MRI/ultrasound-fusion biopsy (fusPbx) with systematic biopsy (sysPbx) in patients undergoing biopsy for AS. Methods: Patients undergoing mpMRI and transperineal fusPbx combined with transrectal sysPbx (comPbx) as surveillance biopsy were investigated. The detection of Gleason score upgrading and reclassification according to Prostate Cancer Research International Active Surveillance criteria were evaluated. Results: Eighty-three patients were enrolled. PCa upgrading was detected in 39% by fusPbx and in 37% by sysPbx (p = 1.0). The percentage of patients who were reclassified in fusPbx and sysPbx (p = 0.45) were 64 and 59% respectively. ComPbx detected more frequently tumour upgrading than fusPbx (71 vs. 64%, p = 0.016) and sysPbx (71 vs. 59%, p < 0.001) and more patients had to be reclassified after comPbx than after fusPbx or sysPbx alone. Conclusions: The combination of fusPbx and sysPbx outperforms both modalities alone with regard to the detection of upgrading and reclassification in patients under AS. Because a high missing rate of significant PCa still exists in both biopsy modalities, a combination of fusPbx and sysPbx should be recommended in these patients.